Please assess the completion status of the following clinical trial:

Trial Title: Comparing the Efficacy of Hybrid, High-dose Dual and Bismuth Quadruple Therapies

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Consecutive H pylori-infected outpatients, at least 20 years of age, with endoscopically proven peptic ulcer diseases or gastritis~Exclusion Criteria:~* previous H pylori-eradication therapy~* ingestion of antibiotics or bismuth within the prior 4 weeks~* patients with allergic history to the medications used~* patients with previous gastric surgery~* the coexistence of serious concomitant illness (for example, decompensated liver cirrhosis, uremia)~* pregnant women

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- 10d bismuth quadruple therapy (Type: ACTIVE_COMPARATOR): rabeprazole 20 mg b.i.d. plus tripotassium dicitrate bismuthate 300 mg, tetracycline 500 mg and metronidazole 250 mg q.i.d. for 10 days.
- 14d hybrid therapy (Type: EXPERIMENTAL): a dual regimen with rabeprazole 20 mg and amoxicillin 1 g b.i.d. for 7 days followed by a quadruple regimen with rabeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg and metronidazole 500 mg b.i.d. for 7 days.
- 14d high-dose dual therapy (Type: EXPERIMENTAL): rabeprazole 20 mg and amoxicillin 750 mg q.i.d. for 14 days

Based on this trial design, predict the completion outcome and termination type (if applicable).